1321614-31-6

Basic information

• Product Name: methyl (4S)-1-[(2S)-3-(acetylsulfanyl)-2-methylpropanoyl]-4-{[(3R)-3-[(tert-butoxycarbonyl)amino]-4-(2,4,5-trifluorophenyl)butanoyl]amino}-L-prolinate
• Synonyms: methyl (4S)-1-[(2S)-3-(acetylsulfanyl)-2-methylpropanoyl]-4-{[(3R)-3-[(tert-butoxycarbonyl)amino]-4-(2,4,5-trifluorophenyl)butanoyl]amino}-L-prolinate
• CAS NO: 1321614-31-6
• Molecular Weight: 603.66
• Mol File: 1321614-31-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: methyl (4S)-1-[(2S)-3-(acetylsulfanyl)-2-methylpropanoyl]-4-{[(3R)-3-[(tert-butoxycarbonyl)amino]-4-(2,4,5-trifluorophenyl)butanoyl]amino}-L-prolinate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl (4S)-1-[(2S)-3-(acetylsulfanyl)-2-methylpropanoyl]-4-{[(3R)-3-[(tert-butoxycarbonyl)amino]-4-(2,4,5-trifluorophenyl)butanoyl]amino}-L-prolinate(1321614-31-6)
• EPA Substance Registry System: methyl (4S)-1-[(2S)-3-(acetylsulfanyl)-2-methylpropanoyl]-4-{[(3R)-3-[(tert-butoxycarbonyl)amino]-4-(2,4,5-trifluorophenyl)butanoyl]amino}-L-prolinate(1321614-31-6)

Safety Data

• Hazardous Substances Data: 1321614-31-6(Hazardous Substances Data)

Upstream product

• 1321614-26-9 1-benzyl 2-methyl (2S,4S)-4-{[(3R)-3-[(tert-butoxycarbonyl)amino]-4-(2,4,5-trifluorophenyl)butanoyl]amino}pyrrolidine-1,2-dicarboxylate 
• 207304-86-7 (2S,4S)-1-benzyl 2-methyl 4-aminopyrrolidine-1,2-dicarboxylate 
• 113490-74-7 4(S)-azido-N-<(phenylmethoxy)carbonyl>-(S)-proline methyl ester 
• 117811-78-6 methyl (2S,4R)-1-benzyloxycarbonyl-4-methanesulfonyloxypyrrolidine-2-carboxylate 
• 1499-56-5 (R)-4-hydroxy-L-proline ethyl ester 
• 64187-48-0 methyl (2S,4R)-1-benzyloxycarbonyl-4-hydroxypyrrolidine-2-carboxylate 

Downstream Products

• 1321614-34-9 (4S)-4-{[(3R)-3-[(tert-butoxycarbonyl)amino]-4-(2,4,5-trifluorophenyl)butanoyl]amino}-1-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-proline 

Relevant articles and documents

PROLINE DERIVATIVES FOR USE IN THE TREATMENT OF DIABETES

The present invention provides novel heterocyclic compounds and methods of preparing such compounds. The compounds of the invention are useful for palliative, curative or prophylactic treatment of diseases or conditions of diabetes and/or hypertension. This invention also relates to pharmaceutical compositions containing the compounds of the present invention, and methods for palliative, curative or prophylactic treatment of diseases or conditions of diabetes and/or hypertension. The present invention also provides pharmaceutical compositions consisting of the heterocyclic compounds along with one or more dyslipidemic agents, antiobesity agents, anti-hyperglycemic agents, antihypertensive agents and anti-inflammatory agents.